TICKERNERD
Menu
SPRYSPRYHealthcare · Biotechnology

SPRY Stock Forecast: ARS Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 14 Sept 2026
$4.50
−5.46% on the day

The 4 Wall Street analysts covering ARS Pharmaceuticals, Inc. hold a median 12-month price target of $23 — +400.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 13 of 100 as at 12 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$473.4M
Ticker Nerd rank
13 / 100
Median analyst target
$23
Analysts covering
4
Revenue$33.7M+114.2% y/y
Operating income−$61.5M
Net income−$62.3M
Free cash flow−$60.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−19.9%
1M
−20.4%
YTD
−61.4%
1Y
−55.1%
From 52W high
−65.5%
From 52W low
0.0%
$5
$13
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SPRY stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores ARS Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
13 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
54
Revisions
48
Accruals
45
Volatility
37
Value
36
Quality
29
Growth
20
Issuance
18
Momentum
6

Size (54): Smaller than most of the companies we track.

Momentum (6): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SPRY stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SPRY, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20$25$30Oct 25Jan 26Apr 26Jul 26SPRYHigh $30Median $23Low $15

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $15Median $23High $30

The green dot is the last close — the median target sits +400.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
13 Aug 2026Leerink PartnersMaintainsOutperform$24 → $18
25 June 2026Leerink PartnersMaintainsOutperform$25 → $24
25 June 2026Leerink PartnersMaintainsOutperform—
28 May 2026Cantor FitzgeraldMaintainsOverweight—
4 Sept 2025Roth CapitalInitiatesBuy—
7 Mar 2025ScotiabankInitiatesSector Outperform—
14 Jan 2025Raymond JamesMaintainsStrong Buy—
13 Jan 2025Leerink PartnersMaintainsOutperform—
8 Oct 2024Cantor FitzgeraldReiteratesOverweight—
20 Sept 2024Leerink PartnersMaintainsOutperform—
16 Sept 2024Cantor FitzgeraldReiteratesOverweight—
9 Sept 2024Cantor FitzgeraldReiteratesOverweight—
20 Aug 2024Cantor FitzgeraldInitiatesOverweight—
13 Aug 2024Raymond JamesUpgradeStrong Buy—
25 July 2024Raymond JamesInitiatesOutperform—
11 Mar 2024WedbushReiteratesOutperform—
5 Mar 2024Leerink PartnersUpgradeOutperform—
13 Nov 2023WedbushMaintainsOutperform—
21 Sept 2023WedbushMaintainsOutperform—
20 Sept 2023William BlairDowngradeMarket Perform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SPRY appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

SPRY vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Sept 2026, ARS Pharmaceuticals, Inc. returned −55.1% against +17.5% for the S&P 500, dividends included.

SPRY vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Oct 25Jan 26Apr 26Jul 26SPRYS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SPRY analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
2
Fundamentals

ARS Pharmaceuticals, Inc. (SPRY) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
168.3×

Cheaper than 4% of US stocks

Price / sales
4.1×

Cheaper than 30% of US stocks

Price / book
38.0×

Cheaper than 3% of US stocks

EV / EBITDA
−2.3×

Cheaper than 73% of US stocks

Growth & margins
Revenue growth (YoY)
114.2%

Higher than 93% of US stocks

Earnings growth (YoY)
114.2%

Higher than 85% of US stocks

Gross margin
61.8%

Higher than 75% of US stocks

Operating margin
−182.6%

Higher than 11% of US stocks

Net margin
−184.2%

Higher than 3% of US stocks

Returns & dividend
Return on equity
−210.3%

Higher than 7% of US stocks

Return on assets
−48.0%

Higher than 8% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

ARS Pharmaceuticals, Inc. (SPRY) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • ARS Pharmaceuticals, Inc. has a market value of $473.4M and an enterprise value of $501.1M.

  • Revenue in the twelve months to 30 June 2026: $116.9M. The latest quarter grew 114.2% year on year.

  • Net income over the same four quarters: −$215.4M, a −184.2% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$196.6M.

  • Shares outstanding: 99.4M.

  • Trailing P/E: 168.3×; forward P/E: −5.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • ARS Pharmaceuticals, Inc. employs 195 people — $600K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Sept 2026

Data provided by Twelve Data

Peers

SPRY vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SPRYARS Pharmaceuticals, Inc.$473.4M
13
RLMDRelmada Therapeutics, Inc.$474.1M
65
PBYIPuma Biotechnology, Inc.$464.1M
92
PRTAProthena Corp. Plc$480.7M
98
CAPRCapricor Therapeutics, Inc.$481.4M
9
EIKNEikon Therapeutics, Inc.$483.7M
1
VOGXVogenx, Inc.$485.9M
1

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own ARS Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SPRY news & analysis

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in ARS Pharmaceuticals Inc. Lawsuit - SPRY

GlobeNewsWire · 14 Sept 2026negative

Levi & Korsinsky, LLP has reminded ARS Pharmaceuticals investors of an October 5, 2026 lead plaintiff deadline in a securities class action lawsuit. The suit covers shareholders who purchased SPRY shares between March 9, 2026 and June 24, 2026.

Why it matters — SPRY watchers would care because a securities class action has been filed against the company and eligible shareholders face a lead plaintiff deadline.

SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit

PRNewsWire · 11 Sept 2026negative

Rosen Law Firm is reminding purchasers of ARS Pharmaceuticals securities during the March 9 to June 24, 2026 Class Period of the October 5, 2026 deadline to file as lead plaintiff in a securities fraud lawsuit against the company.

Why it matters — SPRY watchers may be affected by the securities fraud litigation and should be aware of the upcoming lead plaintiff deadline if they purchased shares during the class period.

Bragar Eagel & Squire, P.C. Reminds ARS Pharmaceuticals Investors to Contact the Firm Before October 5th Seeking Lead Plaintiff Role

GlobeNewsWire · 11 Sept 2026negative

Bragar Eagel & Squire, P.C. reminded investors who purchased or acquired ARS Pharmaceuticals securities between March 9, 2026, and June 24, 2026, to contact the firm before October 5th if they wish to seek the role of lead plaintiff and discuss their legal rights.

Why it matters — SPRY watchers would care because this notice signals a securities class action against the company tied to a defined purchase period, which could affect its legal and financial outlook.

SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law

GlobeNewsWire · 11 Sept 2026negative

A law firm, Schall, Brown & Schwartz LLP, reminded investors of a class action securities fraud lawsuit against ARS Pharmaceuticals. The suit alleges violations of the Securities Exchange Act sections 10(b) and 20(a) and Rule 10b-5.

Why it matters — SPRY investors should be aware of the pending securities fraud litigation and the option to lead the class action, which could have legal and reputational implications for the company.

FAQ

Frequently asked questions about SPRY stock

What is the SPRY stock price forecast for 2026-2027?

The 4 Wall Street analysts covering ARS Pharmaceuticals, Inc. have a median 12-month price target of $23, with estimates ranging from $15 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SPRY stock a buy right now?

Of the 4 analysts covering ARS Pharmaceuticals, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks ARS Pharmaceuticals, Inc. 13 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SPRY?

As at 12 Sept 2026, ARS Pharmaceuticals, Inc. ranks 13 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (54 of 100).

Will SPRY stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +400.0% from the last close, and Ticker Nerd's factor model ranks ARS Pharmaceuticals, Inc. 13 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SPRY stock forecast for 2030?

No analyst covering ARS Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SPRY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $30 over the next 12 months.

How has SPRY stock performed over the past year?

ARS Pharmaceuticals, Inc. returned -55.1% over the 12 months to 14 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does ARS Pharmaceuticals, Inc. do?

Ars Pharmaceuticals Inc. specializes in the biopharmaceutical sector, focusing on the development of innovative, self-administered therapeutics aimed at improving patient outcomes.

What is the latest news on SPRY?

The most recent item we track (GlobeNewsWire, 14 Sept 2026): "Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in ARS Pharmaceuticals Inc. Lawsuit - SPRY". Levi & Korsinsky, LLP has reminded ARS Pharmaceuticals investors of an October 5, 2026 lead plaintiff deadline in a securities class action lawsuit. The suit covers shareholders who purchased SPRY shares between March 9, 2026 and June 24, 2026.

Company

About ARS Pharmaceuticals, Inc.

Ars Pharmaceuticals Inc. specializes in the biopharmaceutical sector, focusing on the development of innovative, self-administered therapeutics aimed at improving patient outcomes. The company's primary purpose is to advance medical solutions for allergy-related indications, enhancing safety and convenience for patients affected by conditions such as allergic reactions requiring rapid intervention. Notable for its emphasis on creating user-friendly delivery mechanisms, Ars Pharmaceuticals tailors its offerings to both patients and healthcare professionals seeking reliable and effective emergency treatments. By addressing critical needs within the healthcare industry, Ars Pharmaceuticals plays a significant role in expanding options in allergy treatment and management. Its contributions to the medical field underscore its ongoing commitment to transforming therapeutic landscapes and meeting pressing health challenges.

CEO Mr. Donn Casale · 195 employees · United States · https://ars-pharma.com